For what is worth here are the latest CLL target prices provided by major financial institutions. Some of them are providing financial and strategic advise to CLL/PDP management.

The institutions who are covering and participating in CLL offerings can obviously influence the market and the share price performance. As, individual investors we can only watch and follow.

Scotia Capital (January 6 2011) dropped the target price from $1.65 to $1.5 per CLL share.

Interestingly Scotia drooped the CLL target price next day after the CLL Operational Update on their progress (or luck of it) in POD1 and Algar production numbers.

RBC (December 15 2010) dropped the target from $1.65 to $1.5

CFSB (December 15 2010) dropped the target from $1.65 to $1.5

RBC and CFSB (Credit Suisse) dropped their target day after CLL December Operational update.

Raymond James (November 12) dropped their target from $2.25 to $1.5